{"id":20,"date":"2021-06-14T21:10:48","date_gmt":"2021-06-14T21:10:48","guid":{"rendered":"https:\/\/www.staff.ncl.ac.uk\/yuelab\/?page_id=20"},"modified":"2024-04-19T12:25:29","modified_gmt":"2024-04-19T12:25:29","slug":"our-people","status":"publish","type":"page","link":"https:\/\/www.staff.ncl.ac.uk\/yuelab\/our-people\/","title":{"rendered":"Our People"},"content":{"rendered":"\n

Current members<\/h4>\n\n\n\n
<\/div>\n\n\n\n
\n

<\/p>\n<\/div><\/div>\n\n\n\n

\n
\n
\n
\"\"<\/figure>
\n
Rhianna Baldwin<\/strong>\nPhD candidate (profile<\/a>)\nBSc (Soton)<\/pre>\n\n\n\n
 I aim to identify and optimise small molecule compound hits, for a metabolic enzyme, by developing a workflow that includes DEL screening, machine learning and cryo EM.<\/em> <\/p>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\"\"<\/figure>
\n
Douglas Ferreira<\/strong>\nDPhil candidate\nMSc (UNIFESP), BSc (UFMG)<\/pre>\n\n\n\n
I am studying a multiprotein complex associated with rare metabolic diseases. I aim to understand the structural features of the proteins of the complex and their interactions using cryo EM and biophysical assays.<\/em><\/p>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\"\"<\/figure>
\n
Richard Heath<\/strong>\nResearch Associate (twitter<\/a>)\nDPhil (Oxon), BSc (Notts)<\/pre>\n\n\n\n
I am using rationalised drug design in combination with structural biology and biophysical assays to identify and develop a novel therapeutic target for Pyridoxine-dependent Epilepsy, a rare disorder of lysine metabolism<\/em>. <\/p>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\"\"<\/figure>
\n
Paola Lanzoni-Mangutchi<\/strong>\nResearch associate\nPhD (Newcastle), MSc BSc (USP, Brazil)<\/pre>\n\n\n\n
I combine structural biology and biophysical assays to characterise and optimise inhibitors for a key member of the complement cascade, as novel therapeutic target for rare blood and immune disorders .<\/em><\/p>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\"\"<\/figure>
\n
Sabrina Mackinnon<\/strong>\nResearch associate (profile<\/a>)\nDPhil (Oxon), BSc (Robert Gordon)<\/pre>\n\n\n\n
I aim to advance new treatment of rare metabolic disorders through the discovery of novel binding sites on disease-associated enzymes. I specialise in fragment screening by X-ray crystallography, paired with enzyme activity and binding assays.<\/em><\/p>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\"\"<\/figure>
\n
Thomas McCorvie<\/strong>\nSenior research associate (profile<\/a>, twitter<\/a>)\nPhD, BSc (QUB)<\/pre>\n\n\n\n
I use structural and biochemical techniques to answer fundamental questions of metabolic enzyme functions, with a special focus on revealing the hidden world of shape shifting enzymes and multiprotein complexes using cryo EM.<\/em><\/p>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\"\"<\/figure>
\n
Katie McLennan<\/strong>\nPhD candidate\nMSci (Glas)<\/pre>\n\n\n\n
I use CRISPR Knock-In technology to insert affinity tags to endogenous proteins for purification, cryo-EM and interaction studies,  hoping to gain a deeper understanding of  protein complexes associated with genetic diseases.<\/em><\/p>\n<\/div><\/div>\n\n\n\n
\"\"<\/figure>
\n
Jiazhi Tang<\/strong>\nResearch associate (profile<\/a>)\nPhD (UCL), BSc (Wuhan)<\/pre>\n\n\n\n
I use the<\/em> crystallographic approach to develop pharmacological chaperones that target a metabolic enzyme, with the goal of developing treatments for a protein misfolding disorder.<\/em><\/p>\n<\/div><\/div>\n\n\n\n
\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n
\n
\"Wyatt<\/figure>
\n
Wyatt Yue<\/strong>\nGroup Leader (profile<\/a>, twitter<\/a>) \nPhD (Lond), MBiochem (Oxon)  <\/pre>\n\n\n\n
Wyatt specialises in the use of structural, biochemical and chemical biology approaches to study human metabolic enzymes and associated rare diseases. He is currently Professor of Structural Biology at the Newcastle University Biosciences Institute.<\/em><\/p>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
Group Photos<\/h4>\n\n\n\n